Moleculin reports Annamycin shows no clinically significant cardiotoxicity in 90-patient pooled analysis

Moleculin Biotech, Inc.

• Pooled analysis of 90 R/R AML patients across 5 trials; 78 had source-verified pre/post ejection fraction assessments.
• No patients met criteria for clinically significant left ventricular dysfunction; mean ejection fraction stable.
• Cardiac safety review conducted by Cleveland Clinic cardio-oncology laboratory.
• Data presented at EHA 2026 Congress; Annamycin dosed beyond conventional anthracycline lifetime limits.
• Management believes results support broader positioning in AML and other oncology indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.